Risk Factors of Survival and Surgical Treatment for Advanced Gastric Cancer with Large Tumor Size

A retrospective analysis of the University of Minnesota (Minneapolis) experience with retinoblastoma is presented. Seventy-five patients were diagnosed with retinoblastoma between 1958 and 1983, of which 53 (71%) had at least one Reese-Ellsworth group V eye. Nineteen group V patients and one group II patient developed extraocular disease recurrence. The cumulative actuarial rate of recurrence at 12 years was 36% for patients with group V disease. The median time from diagnosis to recurrence for unilateral patients was seven months and for bilateral patients 28 months (P = .001). Patients developing extraocular disease had a 10-year actuarial survival rate postrecurrence of 34%. The four long-term survivors of extraocular recurrences had had isolated orbital or local soft tissue recurrences only. Features of group V patients associated with extraocular recurrences were identified by univariate life table analyses. Clinical poor-risk factors included the nongenetic form of the disease (P = .03) and male sex (P = .02). Pathologic poor risk factors included rubeosis (P = .01), undifferentiated histology (P = .03), large tumor size (P = .05), and intraocular extension to the anterior segment (P = .02), retinal pigment epithelium (P = .03), choroid (P less than .001), and optic nerve beyond the lamina cribrosa (P = .02). Treatment-associated poor-risk factors included an optic nerve length of less than 5 mm removed at enucleation (P = .003). Multivariate life table analyses demonstrated the following parameters to be independent poor-prognostic factors: optic nerve length of less than 5 mm removed at enucleation (P = .001), optic nerve involvement (P = .004), and large tumor size (P = .01). These results will help to identify patients with retinoblastoma who are at greatest risk for extraocular recurrence.

Download Full-text

Large tumor size is a poor prognostic factor of gastric cancer with signet ring cell

Medicine ◽

10.1097/md.0000000000017367 ◽

2019 ◽

Vol 98 (40) ◽

pp. e17367 ◽

Cited By ~ 2

Author(s):

Liyuan Zhou ◽

Weihua Li ◽

Shaoxin Cai ◽

Changshun Yang ◽

Yi Liu ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Tumor Size ◽

Signet Ring Cell ◽

Large Tumor ◽

Poor Prognostic Factor ◽

Large Tumor Size ◽

Signet Ring ◽

Ring Cell

Download Full-text

The association between hyperfibrinogenemia and clinicopathological factors, and the survival analysis of gastric cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e16547 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e16547-e16547

Author(s):

Yu Su ◽

Xuecong Zhu ◽

Jing Zuo ◽

Fengling Liu ◽

Yudong Wang ◽

...

Keyword(s):

Gastric Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Tumor Size ◽

Odds Ratio ◽

Fibrinogen Level ◽

Large Tumor ◽

Large Tumor Size ◽

Node Metastasis ◽

Advanced Tumor

e16547 Background: It is reported that hyperfibrinogenemia is commonly seen in gastric cancer. This study aim to discuss the association between fibrinogen level and preoperative clinicopathological factors and to evaluate the value as a predictor of prognosis. Methods: Retrospectively reviewed the medical records and follow-up data of patients with gastric cancer who underwent curative resection from January 2011 to December 2014 at Surgery Department of the Fourth Hospital of Hebei Medical University. Fibrinogen was measured a week before the surgery. Results: A total of 248 cases were enrolled. The means±SD of fibrinogen was 3.28±1.06g/L. Fibrinogen level was higher in older adults(≥60y), advanced tumor, poorly differentiated, deep invasion, lymph node metastasis, large tumor size and in those with high CEA, platelet count, albumin, NLR and PLR,( P< 0.05). All the people were divided by the TNM staging system and found that the plasma fibrinogen was higher in stageⅡand Ⅲ (stageⅠvs. stageⅡ: 2.84±0.72g/L vs. 3.36±1.18g/L, P= 0.009;stageⅠvs. stage Ⅲ: 2.84±0.72g/L vs. 3.43±1.07g/L, P< 0.001), however, there was no difference between stageⅡand Ⅲ( P= 0.662)(our study did not enrolled stage IV patients).When patients were classified into 4 groups according to the T classification, the plasma fibrinogen level gradually increased with increasing depth of cancer invasion (one way ANOVA; P= 0.002). Yet, when the patients who have lymph nodes metastasis classified according to the N classification, the differences among them did not have statistically significance ( P= 0.333). Multivariate analysis revealed that hyperfibrinogenemia had an independent association with advanced cancer (odds ratio,2.686(1.012-7.125); P= 0.047), lymph node metastasis (odds ratio,2.012 (1.012-3.125); P= 0.035) and tumor size(odds ratio,1.949 (1.099-3.454); P= 0.022). Our study aslo suggested that the patients with hyperfibrinogenemia before surgery showed a significantly lower survival rate (Log-Rank test; P< 0.001), hyperfibrinogenemia was a independent predictor on the overall survival, which could predict worse clinical outcome. Conclusions: Hyperfibrinogenemia may be considered a useful biomarker to predict advanced tumor, lymph node metastasis and large tumor size and can be a good predictor of worse clinical outcome.

Download Full-text

Surgical Management and Prognostic Factors Based on 50 Tectal Plate Gliomas

10.21203/rs.3.rs-23446/v1 ◽

2020 ◽

Author(s):

Jie Kang ◽

Chuzhong Li ◽

Peng Zhao ◽

Chunhui Liu ◽

Lei Cao ◽

...

Keyword(s):

Risk Factors ◽

Prognostic Factors ◽

Tumor Size ◽

Surgical Procedure ◽

Preoperative Imaging ◽

Low Grade ◽

Large Tumor ◽

Large Tumor Size ◽

Cystic Changes ◽

Tectal Glioma

Abstract BackgroundThe management and prognostic factors of tectal glioma (TG) remain ambiguous, because it is an extremely rare neoplasm that occurs predominantly in the pediatric population. The objective of this study was to evaluate the risk factors for progression-free survival (PFS) in TG patients after ETV operation, elucidate the radiological features of TG, and propose a treatment protocol.MethodsFrom 2002 to 2018, 50 patients that preoperative imaging manifestations were low-grade TGs were treated at our institute. Clinical features, treatments, radiologic findings, biopsies, and pertinent risk factors were evaluated.ResultsA total of 50 patients with a diagnosis of TG were identified. Twenty-six (52%) patients were males. The median age at diagnosis was 11.5 years (range 0.5–19 years). All patients had symptoms related to obstructive hydrocephalus and were treated with endoscopic third ventriculostomy (ETV). After a median follow-up duration of 59 months (range 11.0–208.0 months), progression occurred in six patients (12%), with a median PFS time of 18.0 months (range 4.0–56.0 months). Twelve patients (24%) underwent a biopsy, one patient (8.3%) was diagnosed with anaplastic oligodendroglioma, one patient (8.3%) was diagnosed with astrocytoma (WHO grade II-III), five patients (41.7%) were diagnosed with pilocytic astrocytoma, and the type of tumor could not be confirmed in five patients (41.7%) due to the small amount of tumor sample, thus, these patients were diagnosed with gliosis. PFS rates at 1 and 5 years were 91.2% ± 4.2% and 84.9% ± 5.9%, respectively. A multivariate model demonstrated that a large tumor size and cystic changes are risk factors for progression.ConclusionETV has been uniformly successful in the management of hydrocephalus caused by TG. A large tumor size and cystic changes are risk factors for progression. Under the condition of safety, a biopsy should be performed. For patients with low-grade TG, ETV is often the only surgical procedure that most patients require.HighlightsTectal gliomas are generally low-grade gliomas with a favorable prognosis.The only surgical procedure that most patients with tectal glioma require is ETV.Under the condition of safety, neuroendoscopy for a pathological diagnosis should be performed.A large tumor size and cystic changes are risk factors for progression.

Download Full-text

Tu1327 – Risk Factors of Early and Advanced Gastric Cancer: A 8 Years Population Study in Northern Italy

Gastroenterology ◽

10.1016/s0016-5085(19)39523-x ◽

2019 ◽

Vol 156 (6) ◽

pp. S-1027

Author(s):

Chiara Miraglia ◽

Ottavia Cavatorta ◽

Marilisa Franceschi ◽

Pellegrino Crafa ◽

Gianluca Baldassarre ◽

...

Keyword(s):

Risk Factors ◽

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Population Study ◽

Northern Italy

Download Full-text

Indications of Lymph Node Metastasis and Survival Analysis in T1N+M0 Gastric Cancer: a Population-Based Study

10.21203/rs.3.rs-36648/v1 ◽

2020 ◽

Author(s):

Peng Jin ◽

Yang Li ◽

Shuai Ma ◽

Wenzhe Kang ◽

Hao Liu ◽

...

Keyword(s):

Risk Factors ◽

Gastric Cancer ◽

Survival Analysis ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Tumor Size ◽

Multivariate Analyses ◽

Invasion Depth ◽

Node Metastasis ◽

Definition Of

Abstract Background Since the definition of early gastric cancer (EGC) was first proposed in 1971, the treatment of gastric cancer with or without lymph node metastasis (LNM) has changed a lot. The present study aims to identify risk factors for LNM and prognosis, and to further evaluate the indications for adjuvant chemotherapy (AC) in T1N + M0 gastric cancer. Methods A total of 1291 patients with T1N + M0 gastric cancer were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate analyses were performed to identify risk factors for LNM. The effect of LNM on overall survival (OS) and cancer-specific survival (CSS) was compared with patients grouped into T1N0-1 and T1N2-3, as the indications for AC. Results The rate of LNM was 19.52%. Multivariate analyses showed age, tumor size, invasion depth, and type of differentiation and retrieved LNs were associated with LNM (p < 0.05). Cox multivariate analyses indicated age, sex, tumor size, N stage were independent predictors of OS and CSS (p < 0.05), while race was indicator for OS (HR 0.866; 95%CI 0.750–0.999, p = 0.049), but not for CSS (HR 0.878; 95% CI 0.723–1.065, p = 0.187). In addition, survival analysis showed the proportion of patients in N+/N0 was better distributed than N0-1/N2-3b. There were statistically significant differences in OS and CSS between patients with and without chemotherapy in pT1N1M0 patients (p༜0.05). Conclusions Both tumor size and invasion depth are associated with LNM and prognosis. LNM is an important predictor of prognosis. pT1N + M0 may be appropriate candidates for AC. Currently, the treatment and prognosis of T1N0M0/T1N + M0 are completely different. An updated definition of EGC, taking into tumor size, invasion depth and LNM, may be more appropriate in an era of precision medicine.

Download Full-text

Assessment of the prognostic significance of clinical and morphological factors for the survival of patients with locally advanced gastric cancer after radical surgical treatment: the experience of the Russian Center

Pharmateca ◽

10.18565/pharmateca.2021.7.102-109 ◽

2021 ◽

Vol 7_2021 ◽

pp. 102-109

Author(s):

N.P. Belyak Belyak ◽

R.V. Orlova Orlova ◽

S.I. Kutukova Kutukova ◽

N.V. Zhukova Zhukova ◽

A.A. Sarmatov Sarmatov ◽

...

Keyword(s):

Gastric Cancer ◽

Surgical Treatment ◽

Advanced Gastric Cancer ◽

Locally Advanced ◽

Prognostic Significance ◽

Locally Advanced Gastric Cancer

Download Full-text

T01.01.24 RISK FACTORS OF EARLY AND ADVANCED GASTRIC CANCER: A 8 YEARS POPULATION STUDY IN NORTHERN ITALY

Digestive and Liver Disease ◽

10.1016/s1590-8658(20)30632-0 ◽

2020 ◽

Vol 52 ◽

pp. S62

Author(s):

O. Cavatorta ◽

C. Miraglia ◽

M. Franceschi ◽

P. Crafa ◽

G. Baldassarre ◽

...

Keyword(s):

Risk Factors ◽

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Population Study ◽

Northern Italy

Download Full-text

Preoperative factors predictive of pathologic upstaging in clinical stage I gastric cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.4_suppl.39 ◽

2019 ◽

Vol 37 (4_suppl) ◽

pp. 39-39

Author(s):

Hayavadhan Thuppal ◽

Patricia Friedmann ◽

John Christopher McAuliffe ◽

Peter Muscarella ◽

Haejin In

Keyword(s):

Risk Factors ◽

Gastric Cancer ◽

Logistic Regression ◽

Neoadjuvant Therapy ◽

Cancer Patients ◽

Tumor Size ◽

Lymphovascular Invasion ◽

Clinical Stage ◽

Gastric Cancer Patients ◽

Stage 1

39 Background: In patients with stage 1 gastric cancer, surgical resection without neoadjuvant therapy is offered as the first line treatment. However, some of these patients are found to have higher stage after resection and miss the opportunity for neoadjuvant therapy. Preoperative patient and tumor characteristics may be predictive of the likelihood of pathological upstaging in stage 1 gastric cancer patients who have not received neo-adjuvant therapy. Methods: The National Cancer Database was queried for patients diagnosed from 2004-2015 with clinical stage 1 gastric adenocarcinoma who had undergone surgical resection without neoadjuvant therapy. Univariate analysis and multivariable logistic regression were conducted to determine pre-operative factors associated with pathological upstaging. Candidate variables examined included age, sex, race, tumor size, histology, grade, tumor location, days to surgery, and lymphovascular invasion. Results: Analysis was conducted on 8,015 clinical stage 1 patients. Overall 1,981 (25%) patients were upstaged. On multivariable logistic regression analysis, significant predictors of upstaging included increasing tumor size [ref : size < 1 cm, 1-2 cm aOR=3.8 (95% CI 2.3-6.1); 2-4 cm aOR=12.4 (7.9-19.5); > = 4cm aOR=25.9 (22.9-56.4)], younger age [ref: > = 75, < 50 aOR=1.7 (1.4-2.1), 50-65 aOR=1.4 (1.2-1.6), 65-75 aOR=1.2 (1.1-1.5)], male gender [aOR=1.16 (1.0-1.3)], presence of diffuse type gastric cancer [aOR=2.3 (1.7-3.2)], mucinous type [aOR=1.7 (1.1-2.5)], or signet ring cell histology [aOR=1.6 (1.3-2.0)] compared to intestinal histology, presence of lymphovascular invasion [aOR=6.0 (5.0-7.1)], and increasing grade [ref: grade 1, grade 2 aOR=2.30 (1.7-3.5); grade 3 aOR=4.9 (3.6- 6.7)]. Conclusions: A quarter of all patients thought to have stage 1 gastric cancer prior to surgery had higher pathologic stage at time of resection. Patients with the above risk factors may be understaged with currently available diagnostic tools. The addition of neoadjuvant therapy should be considered when the above risk factors are present in clinical stage 1 patients.

Download Full-text